Here we discuss evidence of aberrant signaling contributing to MYC transcriptional upregulation and/or enhanced MYC protein stability in a variety of tumor types, including chronic myeloid Leukemia (CML), T-cell acute lymphoblastic leukemia (T-ALL), breast, colorectal, and liver cancers. The gene discussed is MYC; the disease is T-cell acute lymphoblastic leukemia.